Association between tryptophan concentrations and the risk of developing cardiovascular diseases: a systematic review and meta-analysis.

IF 3.9 2区医学 Q2 NUTRITION & DIETETICS Nutrition & Metabolism Pub Date : 2024-10-15 DOI:10.1186/s12986-024-00857-1

Jing Zhang, Xia Jiang, Bo Pang, Dongyun Li, Longfei Kang, Tengda Zhou, Boyu Wang, Lihua Zheng, Chuan-Min Zhou, Lei Zhang

{"title":"Association between tryptophan concentrations and the risk of developing cardiovascular diseases: a systematic review and meta-analysis.","authors":"Jing Zhang, Xia Jiang, Bo Pang, Dongyun Li, Longfei Kang, Tengda Zhou, Boyu Wang, Lihua Zheng, Chuan-Min Zhou, Lei Zhang","doi":"10.1186/s12986-024-00857-1","DOIUrl":null,"url":null,"abstract":"Background: Metabolic regulation of various amino acids have been proven to be effective in preventing cardiovascular disease (CVD). The impact of tryptophan, an essential amino acid, on the risk of developing CVD has not been fully elucidated.Aims: The aim of this meta-analysis was to systematically review evidence of the effects of tryptophan on CVD risk.Methods: The PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases were searched to collect relevant trials from inception to August 2024. The means and hazard ratios (HRs) were extracted and pooled. Subgroup analysis was performed to identify pooled effect estimates, and sensitivity analysis was conducted to assess the robustness of the pooled estimates.Results: Data were collected from 34,370 people under follow-up for CVD events in 13 studies, including cohort studies and case-control studies. They were categorized into three groups on the basis of sample type and indicators: the plasma tryptophan level group, the plasma tryptophan CVD hazard group, and the urinary tryptophan CVD hazard group. The CVD included in this study were coronary artery disease, heart failure, and peripheral artery disease. Twelve studies on plasma tryptophan were meta-analyzed. The plasma tryptophan levels in CVD patients were generally lower than those in individuals without CVD (SMD = -8.57, 95%CI (-15.77, -1.37), P = 0.02). Decreased circulating tryptophan levels are associated with cardiovascular disease risk (HR = 0.85, 95%CI (0.78, 0.92), P < 0.00001).Conclusions: Decreased circulating tryptophan levels are associated with an increased risk of CVD events. Intervention in circulating tryptophan levels may be indicated to help prevent CVD.","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11476920/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12986-024-00857-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Metabolic regulation of various amino acids have been proven to be effective in preventing cardiovascular disease (CVD). The impact of tryptophan, an essential amino acid, on the risk of developing CVD has not been fully elucidated.

Aims: The aim of this meta-analysis was to systematically review evidence of the effects of tryptophan on CVD risk.

Methods: The PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases were searched to collect relevant trials from inception to August 2024. The means and hazard ratios (HRs) were extracted and pooled. Subgroup analysis was performed to identify pooled effect estimates, and sensitivity analysis was conducted to assess the robustness of the pooled estimates.

Results: Data were collected from 34,370 people under follow-up for CVD events in 13 studies, including cohort studies and case-control studies. They were categorized into three groups on the basis of sample type and indicators: the plasma tryptophan level group, the plasma tryptophan CVD hazard group, and the urinary tryptophan CVD hazard group. The CVD included in this study were coronary artery disease, heart failure, and peripheral artery disease. Twelve studies on plasma tryptophan were meta-analyzed. The plasma tryptophan levels in CVD patients were generally lower than those in individuals without CVD (SMD = -8.57, 95%CI (-15.77, -1.37), P = 0.02). Decreased circulating tryptophan levels are associated with cardiovascular disease risk (HR = 0.85, 95%CI (0.78, 0.92), P < 0.00001).

Conclusions: Decreased circulating tryptophan levels are associated with an increased risk of CVD events. Intervention in circulating tryptophan levels may be indicated to help prevent CVD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

色氨酸浓度与心血管疾病发病风险之间的关系：系统回顾和荟萃分析。

背景：各种氨基酸的代谢调节已被证明可有效预防心血管疾病（CVD）。目的：本荟萃分析旨在系统回顾色氨酸对心血管疾病风险影响的证据：方法：检索PubMed、Embase、Web of Science、Cochrane Library和中国国家知识基础设施（CNKI）数据库，收集从开始到2024年8月的相关试验。提取平均值和危险比（HRs）并进行汇总。进行分组分析以确定汇总效应估计值，并进行敏感性分析以评估汇总估计值的稳健性：共收集了 13 项研究（包括队列研究和病例对照研究）中 34,370 名心血管疾病事件随访者的数据。根据样本类型和指标将其分为三组：血浆色氨酸水平组、血浆色氨酸心血管疾病危害组和尿色氨酸心血管疾病危害组。本研究中的心血管疾病包括冠心病、心力衰竭和外周动脉疾病。对 12 项关于血浆色氨酸的研究进行了元分析。心血管疾病患者的血浆色氨酸水平普遍低于非心血管疾病患者（SMD = -8.57，95%CI (-15.77, -1.37), P = 0.02）。循环色氨酸水平降低与心血管疾病风险有关（HR = 0.85，95%CI (0.78，0.92)，P 结论：循环色氨酸水平降低与心血管疾病风险有关：循环色氨酸水平降低与心血管疾病事件风险增加有关。干预循环色氨酸水平有助于预防心血管疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nutrition & Metabolism 医学-营养学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Nutrition & Metabolism publishes studies with a clear focus on nutrition and metabolism with applications ranging from nutrition needs, exercise physiology, clinical and population studies, as well as the underlying mechanisms in these aspects. The areas of interest for Nutrition & Metabolism encompass studies in molecular nutrition in the context of obesity, diabetes, lipedemias, metabolic syndrome and exercise physiology. Manuscripts related to molecular, cellular and human metabolism, nutrient sensing and nutrient–gene interactions are also in interest, as are submissions that have employed new and innovative strategies like metabolomics/lipidomics or other omic-based biomarkers to predict nutritional status and metabolic diseases. Key areas we wish to encourage submissions from include: -how diet and specific nutrients interact with genes, proteins or metabolites to influence metabolic phenotypes and disease outcomes; -the role of epigenetic factors and the microbiome in the pathogenesis of metabolic diseases and their influence on metabolic responses to diet and food components; -how diet and other environmental factors affect epigenetics and microbiota; the extent to which genetic and nongenetic factors modify personal metabolic responses to diet and food compositions and the mechanisms involved; -how specific biologic networks and nutrient sensing mechanisms attribute to metabolic variability.